Zylox-Tonbridge Medical Technology Co., Ltd. disclosed a repurchase of 48,000 H-shares on 17 April 2026 via the Hong Kong Stock Exchange. The repurchase was executed at prices ranging between HKD 23.54 and HKD 24.06 per share, translating into a volume-weighted average cost of HKD 23.88 and an aggregate consideration of approximately HKD 1.15 million.

Following the transaction, issued shares (excluding treasury shares) decreased to 327.99 million, down 0.0143% from the previous day’s 328.05 million. Treasury shares rose correspondingly to 8.35 million, while total issued shares remained unchanged at 336.35 million.

The buyback forms part of the mandate approved on 30 May 2025 that authorises repurchases of up to 31.96 million shares. To date, Zylox-Tonbridge has repurchased 5.53 million shares under this mandate, representing 1.69% of the company’s issued share capital on the authorisation date.

Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or treasury-share sales until 17 May 2026, 30 days after the latest repurchase. All repurchases have been confirmed as compliant with the Main Board Rules and the previously filed explanatory statement.